Completed PHASE1 INTERVENTIONAL NCT00055263

A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies

A Phase I, Open Label, Dose Escalation Study of a New Formulation of Calcitriol (DN-101) for Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies

Sponsor: Novacea

Conditions Neoplasms

Interventions DN-101

Updated 5 times since 2017 Last updated: Jul 24, 2009 Started: Mar 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Neoplasms and is currently completed. Novacea leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novacea

Data source: Novacea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States
• Portland, United States